I undergruppen af patienter, der gennemgik PCI, sås større blødninger almindeligvis hos 9, 7% af de eptifibatid- behandlede patienter mod 4, 6% af dem, der fik placebo.
In the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7% of eptifibatide-treated patients vs 4.6% of placebo-treated patients.